Malcolm C. Smith

86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

François Jamar, Raffaella Barone, Isabelle Mathieu et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 240 citations

Pharmacy, Pharmacokinetics, Pharmacology +8

Immunization With Mutant<i>p53</i>- and<i>K-ras</i>–Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome

David P. Carbone, I. Frank Ciernik, Michael J. Kelley et al. · Journal of Clinical Oncology · 2005 · 169 citations · Full text

Life Sciences, Immunology, Oncology +17

w-Stability of feedback systems

Tryphon T. Georgiou, Malcolm C. Smith · Systems & Control Letters · 1989 · 50 citations

Natural Sciences, Mathematics, Systems Engineering +10

Structural comparison of a 15 residue peptide from the V3 loop of HIV‐1_IIIb and an O‐glycosylated analogue

Xiaolin Huang, Malcolm C. Smith, Jay A. Berzofsky et al. · FEBS Letters · 1996 · 35 citations

Life Sciences, Biochemistry, Immunology +17

Hypersensitivity to rapamycin of BJAB B lymphoblastoid cells.

J E Kay, Malcolm C. Smith, Victoria Frost et al. · PubMed · 1996 · 15 citations

Life Sciences, Immunology, Pharmacology +11